Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

MPS1 inhibition primes immunogenicity of KRAS-LKB1 mutant lung cancer
Shunsuke Kitajima, Tetsuo Tani, Benjamin F. Springer, et al.
Cancer Cell (2022) Vol. 40, Iss. 10, pp. 1128-1144.e8
Open Access | Times Cited: 62

Showing 1-25 of 62 citing articles:

Multifaceted functions of STING in human health and disease: from molecular mechanism to targeted strategy
Zili Zhang, Haifeng Zhou, Xiaohu Ouyang, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 97
Harnessing innate immune pathways for therapeutic advancement in cancer
An-Kang Hu, Li Sun, Hao Lin, et al.
Signal Transduction and Targeted Therapy (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 56
Genomic and Immunophenotypic Landscape of Acquired Resistance to PD-(L)1 Blockade in Non–Small-Cell Lung Cancer
Biagio Ricciuti, Giuseppe Lamberti, Sreekar Reddy Puchala, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 11, pp. 1311-1321
Open Access | Times Cited: 47
The balance of STING signaling orchestrates immunity in cancer
Klara Rasmussen Bollerup Lanng, Emil Leth Lauridsen, Martin R. Jakobsen
Nature Immunology (2024) Vol. 25, Iss. 7, pp. 1144-1157
Closed Access | Times Cited: 44
TREX1 Inactivation Unleashes Cancer Cell STING–Interferon Signaling and Promotes Antitumor Immunity
Tetsuo Tani, Haritha Mathsyaraja, Marco Campisi, et al.
Cancer Discovery (2024) Vol. 14, Iss. 5, pp. 752-765
Closed Access | Times Cited: 39
Unveiling the role of KRAS in tumor immune microenvironment
Miao Xu, Xing Zhao, Ti Wen, et al.
Biomedicine & Pharmacotherapy (2024) Vol. 171, pp. 116058-116058
Open Access | Times Cited: 29
CTLA4 blockade abrogates KEAP1/STK11-related resistance to PD-(L)1 inhibitors
Ferdinandos Skoulidis, Haniel A. Araújo, Minh Truong, et al.
Nature (2024) Vol. 635, Iss. 8038, pp. 462-471
Open Access | Times Cited: 22
cGAS-STING signaling in the tumor microenvironment
Ziqi Liu, Dan Wang, Jiarong Zhang, et al.
Cancer Letters (2023) Vol. 577, pp. 216409-216409
Closed Access | Times Cited: 38
LKB1 controls inflammatory potential through CRTC2-dependent histone acetylation
Shelby E. Compton, Susan M. Kitchen-Goosen, Lisa M. DeCamp, et al.
Molecular Cell (2023) Vol. 83, Iss. 11, pp. 1872-1886.e5
Open Access | Times Cited: 25
Seize the engine: Emerging cell cycle targets in breast cancer
Jesús Fuentes‐Antrás, Philippe L. Bédard, David W. Cescon
Clinical and Translational Medicine (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 12
Engineered extracellular vesicles enable high-efficient delivery of intracellular therapeutic proteins
Ding Ma, An Xie, Jiahui Lv, et al.
Protein & Cell (2024) Vol. 15, Iss. 10, pp. 724-743
Open Access | Times Cited: 9
Immune checkpoint blockade resistance in lung cancer: emerging mechanisms and therapeutic opportunities
Jessica Konen, Haoyi Wu, Don L. Gibbons
Trends in Pharmacological Sciences (2024) Vol. 45, Iss. 6, pp. 520-536
Closed Access | Times Cited: 9
Longitudinal genomic profiling using liquid biopsies in metastatic nonsquamous NSCLC following first line immunotherapy
Haolun Ding, Min Yuan, Yaning Yang, et al.
npj Precision Oncology (2025) Vol. 9, Iss. 1
Open Access | Times Cited: 1
Resistance to PD-1/PD-L1 immune checkpoint blockade in advanced non-small cell lung cancer
Lijun Li, Haihong Pu, Xiaoxin Zhang, et al.
Critical Reviews in Oncology/Hematology (2025) Vol. 209, pp. 104683-104683
Closed Access | Times Cited: 1
Immunogenomic cancer evolution: A framework to understand cancer immunosuppression
Shogo Kumagai, Yusaku Momoi, Hiroyoshi Nishikawa
Science Immunology (2025) Vol. 10, Iss. 105
Closed Access | Times Cited: 1
STK11/LKB1-Deficient Phenotype Rather Than Mutation Diminishes Immunotherapy Efficacy and Represents STING/Type I Interferon/CD8+ T-Cell Dysfunction in NSCLC
Anlin Li, Yuanyuan Wang, Zhixin Yu, et al.
Journal of Thoracic Oncology (2023) Vol. 18, Iss. 12, pp. 1714-1730
Open Access | Times Cited: 21
Targeting LYPLAL1-mediated cGAS depalmitoylation enhances the response to anti-tumor immunotherapy
Yizeng Fan, Yang Gao, Li Nie, et al.
Molecular Cell (2023) Vol. 83, Iss. 19, pp. 3520-3532.e7
Open Access | Times Cited: 21
Harnessing αβ T cell receptor mechanobiology to achieve the promise of immuno-oncology
Ellis L. Reinherz, Wonmuk Hwang, Matthew J. Lang
Proceedings of the National Academy of Sciences (2023) Vol. 120, Iss. 27
Open Access | Times Cited: 17
Emerging mechanisms and implications of cGAS-STING signaling in cancer immunotherapy strategies
Jiawen Zhang, Sihui Yu, Qiao Peng, et al.
Cancer Biology and Medicine (2024), pp. 1-20
Open Access | Times Cited: 8
Second messenger 2'3'-cyclic GMP-AMP (2'3'-cGAMP): the cell autonomous and non-autonomous roles in cancer progression
Xiaoyu Ma, Man Chen, Linghua Meng
Acta Pharmacologica Sinica (2024) Vol. 45, Iss. 5, pp. 890-899
Closed Access | Times Cited: 7
RNAi screens identify HES4 as a regulator of redox balance supporting pyrimidine synthesis and tumor growth
Jing He, Aoxue Wang, Qin Zhao, et al.
Nature Structural & Molecular Biology (2024) Vol. 31, Iss. 9, pp. 1413-1425
Closed Access | Times Cited: 7
KIF2C is a prognostic biomarker associated with immune cell infiltration in breast cancer
Shanshan Liu, Zi‐Wei Ye, Vivian Weiwen Xue, et al.
BMC Cancer (2023) Vol. 23, Iss. 1
Open Access | Times Cited: 16
cGAS-STING at the crossroads in cancer therapy
Rui Wang, Aashiq Hussain, Guo Quanquan, et al.
Critical Reviews in Oncology/Hematology (2023) Vol. 193, pp. 104194-104194
Closed Access | Times Cited: 15
Strategies involving STING pathway activation for cancer immunotherapy: Mechanism and agonists
Xiaohui Pan, Wenxin Zhang, Hongjie Guo, et al.
Biochemical Pharmacology (2023) Vol. 213, pp. 115596-115596
Closed Access | Times Cited: 14
Role of STING in the treatment of non-small cell lung cancer
Wenhua Tang, Wenjie Zhou, Mei Ji, et al.
Cell Communication and Signaling (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 6
Page 1 - Next Page

Scroll to top